Skip to content
OpenCapital
Get started

Guardant Health GH Screening — Total Revenue

Other product segments

Oncology
$204.95M+36.1%
Biopharma and data
$52.98M+16.8%
Licensing and other
$2.14M+15.3%

Similar metrics at other companies

GRAIL, Inc. logo
GRALScreening revenue — Total Revenue
$39.83M+36.7%
GRAIL, Inc. logo
GRALScreening revenue — Cost of revenue
$21.24M+24.1%
Veracyte logo
VCYTTesting revenue — Total Revenue
$135.09M+25.9%
GeneDx Holdings logo
WGSDiagnostic Test — Total Revenue
$101.3M+18.1%
Natera, Inc. logo
NTRATotal Revenue
$696.64M+38.8%
Biodesix, Inc. logo
BDSXDiagnostic Tests — Revenue
$22.29M+36.6%

Other financials

Income statement

See full
Revenue$301.7M+48.3%
Gross profit$196.7M+52.8%
Operating income-$121.4M-9.3%
Net income-$112.1M-17.8%
EPS (diluted)-$0.85-10.4%

Balance sheet

See full
Cash & equivalents$1.1B+37.0%
Total debt$1.7B+30.5%
Total equity-$181.1M+27.8%
Total assets$1.9B+42.5%

Cash flow

See full
Operating cash flow-$65.6M-4.7%
CapEx$5.6M+25.1%
Free cash flow-$71.2M-6.0%

Valuation

See full
Market cap$21B+234%
Enterprise value$21.61B+213%
P/S19.4×+11.8×

Profitability

See full
Gross margin64.9%+3.6pp
Operating margin-41.4%-9.4pp
Net margin-40.1%-8.1pp
FCF margin-22%-6.7pp

Returns & leverage

See full
Return on equity-438.1%-1,655pp
Debt / equity3×—
Current ratio4.7×+0.6×

Where this comes from

Reported directly by Guardant Health in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Guardant Health’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Guardant Health's screening — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Guardant Health's screening — total revenue?
Guardant Health (GH) reported screening — total revenue of $41.59M in Q1 2026.
How has Guardant Health's screening — total revenue changed year-over-year?
Guardant Health's screening — total revenue increased by 632.6% year-over-year, from $5.68M to $41.59M.
What does screening — total revenue mean?
This metric represents the total gross revenue generated from a company's early-detection or screening-focused product portfolio. It captures the commercial adoption and market penetration of diagnostic tests designed for asymptomatic populations or early-stage disease identification. This revenue stream is a critical indicator of the company's expansion into preventative healthcare markets beyond traditional therapeutic or clinical diagnostic segments.